Akanda Corp. (AKAN) vs Silexion Therapeutics Ltd. (SLXN)
A side-by-side comparison of Akanda Corp. and Silexion Therapeutics Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKAN
Akanda Corp.
$1.91HealthcareDelayed quote: Oct 6, 2026, 1:27 PM EDT
SLXN
Silexion Therapeutics Ltd.
$0.26HealthcareDelayed quote: Oct 6, 2026, 1:26 PM EDT
Total return — AKAN vs SLXN
growth of $100 · dividends reinvested · last 2yAKAN -98.9% (-89.5%/yr)SLXN -100.0% (-99.0%/yr)AKAN compounded faster over this window
Log scale — wide-divergence pair
AKAN SLXN
AKAN vs SLXN: by the numbers
- •SLXN is the larger company ($108771 vs $61819 market cap).
- •Both run net losses; SLXN's is the smaller (0.00% vs -17690.19% net margin).
Metrics side by side
Valuation
| Metric | AKAN | SLXN |
|---|---|---|
| P/B ratio | N/A | 2.47 |
Profitability
| Metric | AKAN | SLXN |
|---|---|---|
| Gross margin | -60.46% | 0.00% |
| Operating margin | -1930.99% | 0.00% |
| Net margin | -17690.19% | 0.00% |
| ROE | N/A | -31722.73% |
| ROIC | -242.09% | N/A |
Growth (annualized)
| Metric | AKAN | SLXN |
|---|---|---|
| Revenue CAGR (5Y) | 162.75% | N/A |
Go deeper
Dig into the metrics
Akanda ROESilexion Therapeutics ROEAkanda operating marginSilexion Therapeutics operating marginAkanda revenue growthSilexion Therapeutics revenue growthAkanda free cash flowSilexion Therapeutics free cash flow
Akanda & Silexion Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.